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http://www.biomedcentral.com/1472-6947/13/128RESEARCH ARTICLE Open AccessThe predictability of claim-data-based
comorbidity-adjusted models could be improved
by using medication data
Ji Hwan Bang1,2, Soo-Hee Hwang1,3, Eun-Jung Lee1,4 and Yoon Kim1,5*Abstract
Background: Recently, claim-data-based comorbidity-adjusted methods such as the Charlson index and the
Elixhauser comorbidity measures have been widely used among researchers. At the same time, there have been an
increasing number of attempts to improve the predictability of comorbidity-adjusted models. We tried to improve
the predictability of models using the Charlson and Elixhauser indices by using medication data; specifically, we
used medication data to estimate omitted comorbidities in the claim data.
Methods: We selected twelve major diseases (other than malignancies) that caused large numbers of in-hospital
mortalities during 2008 in hospitals with 700 or more beds in South Korea. Then, we constructed prediction models
for in-hospital mortality using the Charlson index and Elixhauser comorbidity measures, respectively. Inferring
missed comorbidities using medication data, we built enhanced Charlson and Elixhauser comorbidity-measures-
based prediction models, which included comorbidities inferred from medication data. We then compared the
c-statistics of each model.
Results: 247,712 admission cases were enrolled. 55 generic drugs were used to infer 8 out of 17 Charlson
comorbidities, and 106 generic drugs were used to infer 14 out of 31 Elixhauser comorbidities. Before the inclusion
of comorbidities inferred from medication data, the c-statistics of models using the Charlson index were 0.633-0.882
and those of the Elixhauser index were 0.699-0.917. After the inclusion of comorbidities inferred from medication
data, 9 of 12 models using the Charlson index and all of the models using the Elixhauser comorbidity measures
were improved in predictability but, the differences were relatively small.
Conclusion: Prediction models using Charlson index or Elixhauser comorbidity measures might be improved by
including comorbidities inferred from medication data.
Keywords: Severity-of-illness index, Comorbidity, Prescriptions, Drug, Risk-adjustment, Outcome assessmentBackground
When reviewing medical records, claim data, such as
claim data for payment, is much easier to obtain than
clinical data. Thus, in recent years, many researchers
have used claim data to predict prognoses for hospital-
ized patients [1-16]. The most widely adopted methods
of predicting patients’ prognoses based on claim data are
comorbidity-adjusted models such as the Charlson index* Correspondence: yoonkim@snu.ac.kr
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reproduction in any medium, provided the orand the Elixhauser index [17,18]. However, one problem
with comorbidity-adjusted models has been the number
of missed comorbidities in claim data. Two separate
Canadian studies revealed that 33-48% of comorbidities
have been missed in claim data [19,20].
As claim-data-based comorbidity-adjusted models have
become increasingly popular, many researchers have
tried to find methods of improving the predictability of
the comorbidity-adjusted models in order to overcome
these limitations [21-25]. Some investigators have made
efforts to compensate for problems caused by missed
comorbidities in claim data by using drug prescription
information. The Chronic Disease Score (CDS) is ad. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the performance of the CDS-based models in the pre-
diction of prognoses was inferior to that of diagnosis-
based models, including comorbidity-adjusted models
[28,29]. The disappointing outcomes of trials using the
CDS might be attributed to two flaws of the CDS: first,
some drugs included in the CDS can be used for two or
more diseases (or conditions), and second, the drugs by
themselves may not reflect the severity of diseases (or
conditions).
Therefore, it’s fair to assume that an algorithm-based
comorbidity inference method combining medication
data with the indications of each drug could help to
identify missed comorbidities reflecting severity of dis-
eases (or conditions). Our hypothesis is that if missed
comorbidities, traced by medication data, were added to
comorbidity-adjusted models, the predictabilities of the
models might be improved. The purpose of our study is
1) to develop an algorithm-based comorbidity inference
method by combining medication data and the indica-
tions of each drug to identify missed comorbidities; and
2) to evaluate to what degree the predictive performance
of comorbidity-adjusted models can be improved by the
addition of drug-inferred comorbidities identified by the
algorithm.
Methods
Framework of the study
Subjects
We obtained inpatient claim data from all South Korean
hospitals with more than 700 beds during the year 2008.
After excluding malignant diseases, we identified twelve
most responsible diagnoses that caused high numbers of
in-hospital deaths.
Comorbidity-adjusted models for predicting in-hospital
mortality
The Charlson index and Elixhauser comorbidity mea-
sures were used to build comorbidity-adjusted models
for in-hospital mortality (see ‘Tools for adjusting severity
of comorbidities’, below, for details), and the predictive
performance of each model was evaluated.
Inferring missed comorbidities
Using medication, we inferred missed comorbidities
from the claim data.
Comorbidity-adjusted models for predicting in-hospital
mortalities that include drug-inferred comorbidities
We built in-hospital mortality prediction models based
on the Charlson and Elixhauser comorbidity measures
and at the same time included comorbidities inferred
from prescribed medications.Comparison of predictabilities of comorbidity-adjusted
models before and after the inclusion of comorbidities
inferred from medication data
We compared the predictability of the Charlson and
Elixhauser comorbidity-based models that included co-
morbidities inferred from medication data with the ori-
ginal models of the Charlson and Elixhauser indices,
which did not include the comorbidities inferred from
medication data.
Study subjects
The study population consisted of all inpatients in South
Korea who were admitted to any of the 66 hospitals
identified as having more than 700 beds in 2008. To en-
sure the validity and stability of the estimates for
comorbidity-based mortality prediction, we chose to
limit our study to hospitals with more than 700 beds, as
they care for more than half of all South Koreans admit-
ted to hospitals. We obtained the claim data of the hos-
pitals included in the study from the HIRA, the
organization that reviews all the claims of the entire
population of South Korea, regardless of whether they
belong to the national health insurance or the medical
aid program. For patients who admitted twice or more
during the study period, we considered them different
cases. If the study subjects had been admitted the previ-
ous year, in 2007, we also obtained and utilized the claim
data of corresponding cases in 2007 in our construction
of the Charlson-index-based models (see ‘Tools for
adjusting severity of comorbidities’, below, for details).
First, we identified the most responsible diagnoses
(MRDx), which account for 80% of the in-hospital mor-
talities identified in the claims. MRDx meant the princi-
pal diagnoses that were most responsible for the
hospitalization. We then excluded the claims with
MRDx of malignancies because we could not accurately
exclude the cancer patients admitted for palliative care.
Regardless of the quality of care, in-hospital mortalities
of cancer patients admitted for palliative care will inevit-
ably be much higher than those of cancer patients ad-
mitted for active treatment. Thus we did not include the
cases with MRDx of malignant diseases (see next para-
graph for detail). We grouped MRDx according to the
classifications established by the US Agency for Health-
care Research and Quality, but divided acute cerebrovas-
cular diseases into intracranial hemorrhage and ischemic
infarct because these two categories are quite different
in pathophysiology and therapeutic approach [30].
In Korea, patients can do hospital-shopping unlimit-
edly. As a result, ratios of cancer patients who undergo
active treatment and patients who undergo palliative or
terminal care are quietly different even in tertiary care
centers. In this condition, in-hospital mortalities of hos-
pitals which have many palliative or terminal cases must
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this study to develop methodology to rank quality of
care of Korean hospitals. If we adapt comorbidity-
adjusted models to measure quality of care in cancers,
hospitals with many cancer patients for palliative or ter-
minal care must be underrated unjustly. Thus we ex-
cluded all the cancer patients.
Exclusion criteria
We excluded cases that met any of following criteria:
1. Age ≤ 28 days or ≥ 120 years [31].
2. In-hospital stay > 365 days [31].
3. Transferred cases, including both transferred-in and
transferred-out cases: The prognoses of transferred
cases might not reflect qualities of care in
current hospitals.
4. Most responsible diagnoses that have a wide range
of clinical spectrums (ex. sepsis, respiratory failure,
intoxications, other lower respiratory diseases,
cardiac arrest, ventricular fibrillation): They are not
clinically homogeneous categories which are not
suitable for a valid and reliable risk-adjusted mortal-
ity prediction. This is the first large study which
adapted comorbidity adjusted method, thus we de-
cided to include relatively homogenous groups.
Moreover, in these cases, the most responsible diag-
noses, per se, might be results or complications of
treatment rather than POA (present on illness).
Tools for adjusting the severity of comorbidities
In our study, we adopted the Charlson index with Deyo’s
application as well as the Elixhauser comorbidity mea-
sures for adjusting the severity of comorbidities. In a
comorbidity-adjusted model, comorbidity indicates an
associated disease or condition existing before the point
of admission and is used interchangeably with Present
on Admission (POA). In contrast, a disease or condition
that occurred after hospitalization is called a complica-
tion or non-POA [19].
Charlson index
The Charlson index is the most frequently used method
for adjusting the severity of comorbidities in studies
based on claim data [17]. In 1987, M.E. Charlson and
her colleagues reported 17 comorbidities that influence
the prognoses of hospitalized patients, and they gave a
“weight” of 1 to 6 to each individual comorbidity, de-
pending on the strength of the treatment outcome: the
higher weight, the worse the prognosis tends to be
(Additional file 1: Table S1). The sum of weights for co-
morbid conditions indicates the severity of comorbidi-
ties for each individual case. Widely accepted among
researchers, the Charlson index has been used to buildnation-wide prognoses prediction models in many
countries [31-33].
To apply the Charlson index, it is important to distin-
guish a comorbidity (or POA) from a complication (or
non-POA) in associated diagnoses (not MRDx). Deyo’s
application has been used more than any other to make
this distinction [21]. In Deyo’s application, chronic dis-
eases (or conditions) are classified as POA conditions. In
addition, according to Deyo’s application, diseases (or
conditions) that are not explicitly chronic must be men-
tioned in the previous data from at least one year prior
to the index admissions in order to be considered as
POA conditions; otherwise, they are regarded as non-
POA conditions (Additional file 1: Table S1).Elixhauser comorbidity index
Elixhauser et al. found 31 comorbidities that influence
the prognoses of hospitalized patients (when hyperten-
sion is divided between uncomplicated hypertension and
complicated hypertension) (Additional file 1: Table S2)
[18]. In the Elixhauser comorbidity index, existence or
non-existence of specific comorbidities is used to adjust
the severity of comorbidities. The Elixhauser comorbid-
ity index is generally accepted as similar or superior to
the Charlson index in its prediction of prognoses
[34-37]. However, Elixhauser-index-based models could
be unstable due to the high number of independent vari-
ables in the model.
In order to discriminate between POA conditions
and non-POA conditions, the Diagnosis-related Group
(DRG) screening method was used in the Elixhauser
comorbidity measures. The DRG screening method
classified secondary diagnoses as non-POA when the
method determined that secondary diagnoses belonged
to the same disease category as the MRDx and/or re-
sulted from MRDx; otherwise, they were considered
POA conditions.
Because the International Classification of Diseases-
10th Edition (ICD-10) has been used for diagnostic cod-
ing in South Korea since 1995, Quan’s algorithm was
applied to convert ICD-10 diagnoses to the ICD-9-CM
diagnoses on which the Charlson index and Elixhauser
comorbidity index were originally based [38].Inferring missed comorbidities
In order to infer missed comorbidities in the claim data,
we used medication data. Specifically, drugs had to meet
all of following criteria to be used for the inference of
missed comorbidities: 1) prescribed one or more times
during hospitalization; 2) used for treatment of diseases
(or conditions) included in Charlson index and/or
Elixhauser comorbidity measures; and 3) used exclu-
sively for one disease entity.
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1) Drugs that can be used for more than one disease en-
tity under the prescription guidance of the HIRA [39];
2) Drugs possibly used in relatively mild abnormal con-
ditions including topical agents; 3) Antineoplastics;
4) Parenteral drugs. For example, paroxetine, one of the
most frequently prescribed antidepressants, was ex-
cluded because it could be used to treat other conditions
such as obsessive-compulsive disorder. In the Elixhauser
comorbidity measures, uncomplicated hypertension and
complicated hypertension are classified as different en-
tities. If a patient was prescribed an antihypertensive, we
could not determine whether he or she had uncompli-
cated hypertension or complicated hypertension. Thus,
we excluded antihypertensives. Similarly, in both the
Charlson index and the Elixhauser comorbidity index,
uncomplicated diabetes is distinguished from compli-
cated diabetes. Thus, we excluded antidiabetic drugs.
Antineoplastic drugs were excluded because they could
be used not only for cancer patients, but also for pa-
tients with connective tissue diseases and transplantation
patients. Parenteral drugs were excluded because many
parenteral drugs were used to treat conditions that ap-
peared after admission.
Finally, to eliminate non-POA conditions from the in-
ferred comorbidities, the DRG screening method of the
Elixhauser comorbidity measure was used (see ‘Tools for
adjusting severity of comorbidities’ for details) [18].
Building prediction models for in-hospital mortalities
In this study, we built prediction models for in-hospital
mortalities using multiple logistic regression analyses.
The independent variables of each model were: age, sex,
status of health insurance (the National Health Insur-
ance beneficiaries or Medical Aids beneficiaries), admis-
sion category (emergency admission or not), operative
status (operated on or not), and adjusted severity of co-
morbidities measured by the Charlson index or Elixhauser
comorbidity measures. Following our application of the
aforementioned methods, we built four models for each
disease in the study, as indicated below.
1. Charlson models: Charlson-index-based
comorbidity-adjusted models that use only comor-
bidities described in the claim data.
2. Elixhauser models: Elixhauser-comorbidity-measure-
based models that use only comorbidities described
in the claim data.
3. Enhanced Charlson models: Charlson-index-based
comorbidity-adjusted models that use both comor-
bidities described in the claim data and inferred
from medication data.
4. Enhanced Elixhauser models: Elixhauser-
comorbidity-measure-based comorbidity-adjustedmodels that use both comorbidities described in the
claim data and inferred from medication data.
Statistic validation of the models
We calculated the c-statistic for each model and com-
pared them to measure whether the addition of drug-
inferred comorbidities could improve the predictive
power of the Charlson and Elixhauser comorbidity indi-
ces. The c-statistic is an indicator of predictability. If the
c-statistic = 0.5, it means the predictability of the model
is 0%. If the c-statistic = 1.0, it means the predictability
of the model is 100%. Additionally, we carried out
Hosmer-Lemeshow Goodness-of-Fit tests to examine
the fitness of the models. We performed bootstrapping
method to calculate a 95% confidence interval of the
c-statistics of each model.
Changes of Charlson index scores in original and
enhanced models were compared by Wilcoxon signed
rank test.
All the statistical analyses were performed by SAS v9.2
(SAS Institute Inc., Cary, NC, USA).
Ethics statement
According to the policy of our institution (Seoul Na-
tional University, College of Medicine), researches re-
quested by the government to the public interests are to
be exempted from approval by the Institutional Review
Board (IRB). Our study was proposed by the govern-
mental organization of Korea (The HIRA). Therefore
this study was accomplished without ethical review of
the IRB.
Results
General characteristics of the study population
Total 706,321 admissions with 33 MRDx were account
for 80% of in-hospital mortalities during study period.
Excluding the cased with MRDx of wide range of clinical
spectrums and malignancies, finally 12 MRDx with
247,712 admission cases were included in this study
(Table 1). The overall in-hospital mortality rate was 6.8%
(16,962 cases). In the 12 MRDX, intracranial hemorrhage
was the most frequent MRDx of in-hospital mortalities,
followed by pneumonia, ischemic infarct, acute myocar-
dial infarction, and non-alcoholic liver disease. The major-
ity of study cases were adults (median age: 61 years,
interquartile range: 47-71), except cases of pneumonia
(median age: 4 years, interquartile range: 1-63), and 59.1%
of the cases (146,484 cases) were male.
Charlson models and enhanced Charlson models
Among the 965 drugs (by generic name) prescribed in
the study cases, 55 drugs were selected to infer missed
comorbidities of the Charlson index in the claim data
after the author’s (JH Bang) review of the patients’
Table 1 Most responsible diagnoses which were account for 80% of in-hospital mortalities during study period
MRDx1 No. of death No. of admission Male (%) Mortality rate (%) Age, years (IQR2) LOS3, days (IQR2)
Liver cancer 3,657 56,433 78.4 6.5 60 (52-67) 6 (4-11)
Lung cancer 3,591 66,116 73.5 5.4 65 (57-71) 6 (4-11)
Stomach cancer 2,421 75,545 68.2 3.2 59 (50-68) 5 (3-11)
Sepsis 1,867 7,090 54.4 26.3 52 (1-72) 7 (4-15)
ICH4* 1,661 13,340 50.6 12.5 60 (49-70) 18 (8-30)
Pneumonia* 1,342 48,587 56.7 2.8 4 (1-63) 6 (5-9)
Leukemia 1,015 16,796 58.5 6.0 39 (13-58) 8 (3-24)
Pancreatic cancer 967 12,509 60.2 7.7 64 (55-70) 6 (2-13)
Other gastrointestinal cancer 937 13,863 52.3 6.8 64 (55-71) 7 (4-16)
Colon cancer 913 49,480 57.7 1.9 62 (53-69) 4 (3-7)
Ischemic infarct* 882 30,349 56.3 2.9 68 (58-75) 9 (6-15)
AMI5* 855 13,912 68.7 6.1 65 (54-73) 7 (5-9)
Non-alcoholic liver disease* 726 15,246 58.6 4.8 53 (44-65) 8 (4-14)
Intracranial injury* 620 9,676 69.5 6.4 53 (35-68) 10 (4-19)
Non-Hodgkin’s lymphoma 583 16,747 60.5 3.5 56 (43-67) 5 (2-11)
Rectal and anal cancer 581 34,853 63.2 1.7 61 (53-69) 5 (4-9)
Respiratory failure 571 2,317 60.0 24.6 64 (8-75) 9 (5-20)
Breast cancer 563 48,483 0.42 1.2 48 (42-56) 3 (2-8)
CRF6* 553 17,921 54.6 3.1 59 (47-69) 6 (4-16)
Intoxication 433 4,751 57.0 9.5 50 (37-65) 3 (2-7)
COPD7* 407 12,162 64.4 3.3 68 (56-76) 8 (5-12)
Gastrointestinal bleeding 406 15,039 72.1 2.7 58 (46-70) 6 (3-9)
Alcoholic liver disease* 401 7,983 88.0 5.0 51 (45-59) 8 (5-14)
Aspiration pneumonia* 398 2,573 68.7 15.5 72 (60-80) 14 (7-26)
CHF8* 394 7,892 40.0 5.0 74 (66-80) 8 (5-12)
Other lower respiratory disease 363 8,818 58.4 4.1 61 (50-71) 6 (3-10)
ARF9 344 3,406 55.2 10.1 67 (50-76) 9 (5-16)
Esophageal cancer 342 7,873 92.7 4.3 65 (58-70) 6 (3-13)
Head and neck cancer 297 11,669 80.1 2.6 59 (50-68) 6 (2-12)
Coronary atherosclersis* 287 68,071 59.2 0.4 63 (54-70) 3 (2-5)
Secondary malignacy 282 6,055 52.6 4.66 60 (50-75) 8 (4-16)
Cardiac arrest 278 766 64.8 36.3 59 (47-70) 7 (2-20)
Sum 28,937 706,321 59.7 4.1 60 (48–69) 5 (3-11)
1 Most responsible diagnoses, 2 Interquartile range, 3 Length of stay, 4 Intracranial hemorrhage, 5 Acute myocardial infarction, 6 Chronic renal failure, 7 Chronic
obstructive pulmonary disease, 8 Congestive heart failure, 9 Acute renal failure.
*Cases with most responsible diagnoses marked with asterisks were selected for final analysis.
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(Additional file 1: Table S3).
Out of the 17 comorbidity conditions on the Charlson
index, the following eight conditions could be inferred
from medication data: congestive heart failure, periph-
eral vascular disease, cerebrovascular disease, dementia,
chronic pulmonary disease, connective tissue disease
and rheumatic disease, renal disease, and AIDS. Of the
26,113 inferred and/or documented cases of peripheral
vascular disease, 74.3% (19,406 cases) were detected onlyby inferring from medication data. With regard to other
medical conditions, the percentage of cases inferred by
medication data were as follows: congestive heart failure
(41.5%), chronic pulmonary disease (39.0%), renal dis-
ease (7.3%), cerebrovascular disease (5.6%), AIDS (3.8%),
connective tissue disease/rheumatic disease (1.5%), and
dementia (1.2%) (Table 2). Changes of Charlson index
scores in original and enhanced models were statistically
significant in all the 12 pairs (P < 0.01 in all the pairs,
data not shown).





Claim data ∩ Prescribing
information3 (A∩B)
Fraction of additional comorbidities inferred by
prescribing information {(A∪B)-A}/(A∪B)
Peripheral vascular disease 6,707 21,858 2,452 74.3%
Congestive heart failure 4,531 4,159 946 41.5%
Chronic pulmonary
disease
30,656 36,129 16,517 39.0%
Renal disease 8,298 1,054 400 7.3%
Cerebrovascular disease 8,196 638 153 5.6%
AIDS 51 10 8 3.8%
Connective tissue disease/
rheumatic disease
2,727 114 72 1.5%
Dementia 3,811 261 216 1.2%
1 No. of cases of each Charlson index comorbidity identified from claim data, 2 No. of cases each Charlson index comorbidity inferred from drug prescribing
information, 3 No. cases of each Charlson index comorbidity identified (or inferred) both claim data and drug prescribing information.
Table 3 Results of original Charlson models1 and enhanced Charlson2 models
MRDx3 c statistics Hosmer-Lemeshow test
Charlson4 Enhanced5 Charlson4 Enhanced5
(95% CI6) (95% CI6) chi-square (P) chi-square (P)
ICH7 0.655 0.654 6.2 (0.63) 10.0 (0.27)
(0.642-0.669) (0.641-0.667)
Pneumonia 0.882 0.884 28.9 (<0.01) 26.7 (0.00)
(0.876-0.888) (0.878-0.890)
Ischemic infarct 0.715 0.716 10.5 (0.23) 12.7 (0.12)
(0.698-0.750) (0.699-0.733)
AMI8 0.766 0.770 9.2 (0.32) 10.9 (0.21)
(0.750-0.782) (0.754-0.786)
Non-alcoholic liver disease 0.740 0.750 30.3 (<0.01) 32.2 (<0.01)
(0.724-0.756) (0.734-0.766)
Intracranial injury 0.724 0.724 18.9 (0.02) 16.3 (0.04)
(0.705-0.743) (0.705-0.747)
CRF9 0.752 0.756 5.6 (0.69) 5.0 (0.76)
(0.733-0.771) (0.737-0.775)
COPD10 0.719 0.726 3.6 (0.89) 2.8 (0.95)
(0.696-0.742) (0.704-0.748)
Alcoholic liver disease 0.696 0.708 30.5 (<0.01) 27.1 (<0.01)
(0.673-0.719) (0.685-0.731)
Aspiration pneumonia 0.658 0.658 12.4 (0.13) 8.8 (0.36)
(0.631-0.685) (0.631-0.685)
CHF11 0.633 0.641 6.2 (0.62) 4.7 (0.80)
(0.604-0.662) (0.613-0.669)
Coronary atherosclerosis 0.847 0.861 16.3 (0.04) 21.0 (0.01)
(0.827-0.867) (0.842-0.880)
1 & 2 Multiple logistic regression models for predicting in-hospital mortalities composed of age + sex + status of health insurance + admission category (emergent
or not) + operation (yes or no) + Charlson index score, before (Charlson models) and after (enhanced Charlson models) adding comorbidities inferred by drug
prescription information, 3 Most responsive diagnoses, 4 Charlson models, 5 Enhanced Charlson models, 6 95% confidence interval calculated by bootstrapping,
7 Intracranial hemorrhage, 8 Acute myocardial infarction, 9 Chronic renal failure, 10 Chronic obstructive pulmonary disease, 11 Congestive heart failure.
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model and the enhanced models using c-statistics, the
enhanced models were slightly superior to the original
in all but three MRDx categories (See Additional file 1:
Tables S5-S28 to review the model coefficients). Im-
provements of c-statistics, however, were relatively
small and c-statistics of the enhanced models were
within 95% confidence intervals of the original Charlson
models (Table 3). The c-statistics of the original models
ranged from 0.633 (congestive heart failure) to 0.882
(pneumonia) while those of the enhanced models
ranged from 0.641 (congestive heart failure) to 0.884
(pneumonia). In models for intracranial injury and aspir-
ation pneumonia, the c-statistics of the original and en-
hanced models were equal. In intracranial hemorrhage, the
c-statistic of the original model was slightly higher than that
of the enhanced model (0.655 and 0.654, respectively).
Elixhauser models and enhanced Elixhauser models
After the author’s (JH Bang) review of the patients’ medi-
cation data and HIRA’s prescriptions guidelines, 106
drugs were selected to infer missed comorbidities on the
Elixhauser index in the claim data (Additional file 1:
Table S4). Out of 31 comorbidity conditions on the
Elixhauser index, the following fourteen conditions
could be inferred from medication data: congestive heart
failure, cardiac arrhythmia, peripheral vascular disorders,
other neurological disorders, chronic pulmonary disease,
hypothyroidism, renal failure, liver disease, AIDS, rheuma-
toid arthritis and collagen vascular diseases, weight loss,







Peripheral vascular disorders 6,707 21,858 2,452
Psychoses 1,719 4,614 1,420
Chronic pulmonary disease 26,038 36,129 16,517
Congestive heart failure 5,423 4,159 1,419
Deficiency anemia 12,518 12,949 6,927
Depression 8,267 4,420 2,134
Other neurological disorders 7,037 2,900 1,491
Hypothyroidism 5,346 2,792 1,909
Renal failure 4,952 1,054 400
Weight loss 7,445 556 130
AIDS 35 10 8




Liver disease 21,051 255 187
1 No. of cases of each Elixhauser comorbidity identified from claim data, 2 No. of ca
3 No. cases of each Elixhauser comorbidity identified (or inferred) both claim data aenhanced Charlson models, in the 26,113 inferred and/
or documented cases of peripheral vascular disease,
large numbers of cases (19,406 cases, or 74.3%) were
detected only by inferring from medication data. Per-
ipheral vascular disease was followed by psychosis
(65.0%), chronic pulmonary disease (43.0%), congestive
heart failure (33.6%), deficiency anemia (32.5%), de-
pression (21.7%), other neurological disorders (16.7%),
hypothyroidism (14.2%), renal failure (11.7%), weight
loss (5.4%), AIDS (5.4%), cardiac arrhythmia (3.1%),
rheumatoid arthritis/collagen vascular diseases (2.0%),
liver disease (0.3%) (Table 4).
The c-statistics of the original Elixhauser model ranged
from 0.699 (congestive heart failure) to 0.917 (pneumonia)
while those of the enhanced models ranged from 0.707
(congestive heart failure) to 0.920 (pneumonia) (Table 5,
see Additional file 1: Tables S29-S52 to review the model
coefficients). Comparing the predictive power of the ori-
ginal and enhanced Elixhauser models using c-statistics,
the enhanced models were slightly superior to the original
models in all MRDx categories, although once again im-
provement of c-statistics was relatively small and majority
of c-statistics of the enhanced models were within 95%
confidence intervals of the original Elixhauser, except for
acute myocardial infarction (Table 5).
Discussion
In this study, we showed that the predictability of
comorbidity-adjusted models can be improved by the
addition of missed comorbidities inferred from patients’
medication data.from drug prescribing information (N = 247,712)
Prescribing
A∩B)
















ses each Elixhauser comorbidity inferred from drug prescribing information,
nd drug prescribing information.
Table 5 Results of original Elixhauser models1 and enhanced Elixhauser2 models
MRDx3 c statistics Hosmer-Lemeshow test
Elixhauser4 Enhanced5 Elixhauser4 Enhanced5
(95% CI6) (95% CI6) chi-square (P) chi-square (P)
ICH7 0.736 0.748 7.3 (0.50) 7.8 (0.46)
(0.723-0.749) (0.736-0.760)
Pneumonia 0.917 0.920 26.8 (<0.01) 26.8 (<0.01)
(0.912-0.922) (0.915-0.925)
Ischemic infarct 0.787 0.805 14.6 (0.07) 17.2 (0.03)
(0.767-0.807) (0.786-0.824)
AMI8 0.809 0.825 35.8 (<0.01) 35.4 (<0.01)
(0.795-0.823) (0.811-0.839)
Non-alcoholic liver disease 0.798 0.811 24.1 (<0.01) 25.4 (<0.01)
(0.782-0.814) (0.796-0.826)
Intracranial injury 0.778 0.790 12.3 (0.14) 13.5 (0.10)
(0.759-0.797) (0.771-0.809)
CRF9 0.832 0.840 19.3 (0.01) 28.0 (<0.01)
(0.816-0.848) (0.825-0.855)
COPD10 0.810 0.815 8.7 (0.37) 12.2 (0.14)
(0.789-0.831) (0.795-0.835)
Alcoholic liver disease 0.777 0.788 8.9 (0.35) 3.2 (0.92)
(0.753-0.801) (0.764-0.812)
Aspiration pneumonia 0.730 0.734 3.2 (0.92) 8.1 (0.42)
(0.703-0.757) (0.707-0.761)
CHF11 0.699 0.707 3.5 (0.90) 4.7 (0.79)
(0.672-0.726) (0.680-0.734)
Coronary atherosclerosis 0.881 0.889 22.7 (<0.01) 14.2 (0.08)
(0.862-0.900) (0.869-0.909)
1 & 2 Multiple logistic regression models for predicting in-hospital mortalities composed of age + sex + status of health insurance + admission category (emergent
or not) + operation (yes or no) + presence of each Elixhauser comorbidity (yes or no), before (Elixhauser models) and after (enhanced Elixhauser models) adding
comorbidities inferred by drug prescription information, 3 Most responsive diagnoses, 4 Elixhauser models, 5 Enhanced Elixhauser models, 6 95% confidence
interval calculated by bootstrapping, 7 Intracranial hemorrhage, 8 Acute myocardial infarction, 9 Chronic renal failure, 10 Chronic obstructive pulmonary disease,
11 Congestive heart failure.
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to use medication data to improve the predictive power
of the comorbidity index. However, in the CDS, there is
little consideration for drugs used to treat two or more
diseases [26,27]. For example, epilepsy is considered as a
comorbid condition in the CDS, yet many antiepileptic
drugs are used to treat other conditions such as neuro-
genic pain and mood disorders. Consequently, inaccur-
ate inference of comorbid conditions can occur, which
may negatively affect predictability in the CDS system.
In this study, we used drugs that are used exclusively to
treat one disease category. Thus, in our study, we elimi-
nated inaccurate inferences of comorbid conditions caused
by drugs that are used to treat two or more conditions.
Other researchers have also tried to combine diagnosis-
based scores (ex. Charlson index) and pharmacy-based
scores (ex. CDS-1 or CDS-2). These studies showed thatthe predictabilities of combined models were generally
better than those of models composed only of diagnosis-
based scores [29,40,41]. Yet, in our opinion, these at-
tempts at combined models had additional problems.
First, these models created the potential for double count-
ing and/or different counting of risk scores for cases with
the same comorbidity. For example, if both patient A and
patient B have rheumatoid arthritis (RA) and are pre-
scribed gold salt to relieve RA, but the diagnosis of RA is
missed only in the claim data of patient A, the risk scores
of the two patients would be different even though they
have the same comorbidity. In this example, the same
pharmacy-based scores are assigned to both patient A and
patient B because they take same medication, but the
diagnosis-based score is assigned only to patient B. Sec-
ond, by combining diagnosis-based scores and pharmacy-
based scores, the number of independent variables (i.e.,
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creases. An increased number of independent variables
may result in the instability of a prediction model, espe-
cially when the number of study cases is relatively small.
In our study, we used the medication data only to infer
missed comorbidities, and inferred comorbidities were
directly included in comorbidity-adjusted models with-
out increasing the number of independent variables.
Consequently, our study is free from the above two
problems.
To find missed comorbidities, we included only those
drugs that are used to treat a single disease entity. One
potential concern was that this method would result in
an uneven distribution of additional comorbidities in-
ferred from the medication data. For example, the ma-
jority of patients with rheumatologic or connective
tissue diseases have been prescribed immunosuppres-
sants. Because such agents might be used to treat solid
tumors or hematologic malignancies, we did not use im-
munosuppressants to infer missed comorbidities. As a
result, the number of drug-inferred comorbidities of
rheumatologic or connective tissue diseases was rela-
tively small (Tables 2 and 4). Therefore, it would be rea-
sonable to suspect that the uneven detection of missed
comorbidities might decrease the fitness of the models.
However, our study showed that fitness, as shown by the
Hosmer-Lemeshow Goodness-of-Fit tests, was similar
between the original and enhanced Charlson models as
well as between the original and enhanced Elixhauser
models (Tables 3 and 5). Thus, we could affirm that un-
even detection of missed comorbidities did not consti-
tute an unacceptable problem.
Another remarkable finding of our study is that using
medication data to infer missed comorbidities improved
the predictabilities of Elixhauser models more than those
of Charlson models. We believe that these differences
were related to the respective characteristics of the
Charlson and Elixhauser models. In the Charlson index,
the sum of the weight of comorbidities is used to adjust
the severity of comorbidities without consideration to
the interaction of MRDx and the specific comorbidity
[17]. In the Elixhauser index, however, interaction be-
tween MRDx and each comorbidity is considered [18].
As a result, inferred comorbidities might increase the
predictabilities of Elixhauser models more than those of
Charlson models.
Another important consideration is that although we
used the DRG screening method to differentiate between
drug-inferred diagnoses that were POA and those that
were non-POA, it is possible that POA conditions de-
fined by DRG screening method could truly be non-
POA conditions. However, in our study, the majority of
drug-inferred comorbidities were chronic conditions
that were not thought to develop after hospitalization(Tables 2 and 4). Thus, we thought that most of the
drug-inferred comorbidities were developed before or at
the time of hospitalization.
Our study has some limitation: first, we excluded can-
cer cases and cases diagnosed to have a wide range of
clinical spectrums which occupied major portion of in-
hospital mortalities, thus further studies are warranted
to generalize the findings of our study; second, improve-
ment of c-statistics in enhanced models was relatively
small and most of c-statistics of enhanced models were
within 95% confidence intervals of original models, thus
to confirm the results of our study, additional studies
should be followed.
Conclusion
In conclusion, predictabilities of comorbidity-adjusted
models might be improved by the use of medication data
to infer missed comorbidities.
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